Skip to content
TrialScanner

NCT02244606

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Phase 2CompletedSCYXLead

Registry record

Lead sponsor
Scynexis, Inc.
Conditions
Mycoses; Candidiasis, Invasive; Candidemia
Primary completion
Jun 2016Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02244606 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02244606: Oral Ibrexafungerp (SCY-078)... | TrialScanner